Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAB1 | Q9Y478 | 3/20 | 1.00 |
| ▸ | PRKAB2 | O43741 | 2/20 | 1.00 |
| ▸ | PRKAG1 | P54619 | 2/20 | 1.00 |
| ▸ | PRKAA2 | P54646 | 2/20 | 1.00 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 1.00 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 1.00 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 1.00 |
| ▸ | KDR | P35968 | 12/20 | 0.67 |
| ▸ | FLT1 | P17948 | 4/20 | 0.67 |
| ▸ | FLT4 | P35916 | 4/20 | 0.67 |
| ▸ | PLK4 | O00444 | 1/20 | 0.67 |
| ▸ | AURKA | O14965 | 1/20 | 0.67 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.67 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.67 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.67 |
| ▸ | INSR | P06213 | 1/20 | 0.67 |
| ▸ | CDK1 | P06493 | 1/20 | 0.67 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.67 |
| ▸ | CDK2 | P24941 | 1/20 | 0.67 |
| ▸ | MARK3 | P27448 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13126003 | 0.84 | PRKAB1 (0.72) | PRKAB1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL17441984 | 0.81 | PRKAB1 (0.68) | PRKAB1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL19110545 | 0.80 | PRKAB1 (0.67) | PRKAB1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL19110525 | 0.80 | PRKAB1 (0.67) | PRKAB1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL2810629 | 0.80 | KDR (1.00) | PRKAB1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL3766934 | 0.79 | PRKAB1 (0.66) | PRKAB1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL2284618 | 0.79 | PRKAB2 (0.65) | PRKAB1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL19110512 | 0.78 | PRKAB1 (0.63) | PRKAB1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL17442402 | 0.78 | PRKAB1 (0.63) | PRKAB1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL17531601 | 0.77 | PRKAB1 (0.62) | PRKAB1PRKAB2PRKAG1PRKAA2PRKAA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017516-B2 | BMP inhibitors and methods of use thereof | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10017516-B2 | BMP inhibitors and methods of use thereof | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170334918-A1 | BMP Inhibitors and Methods of Use Thereof | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2017-11-23 | — | — | US | disclosed |
| US-20170334918-A1 | BMP Inhibitors and Methods of Use Thereof | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2017-11-23 | — | — | US | disclosed |
| US-20170334918-A1 | BMP Inhibitors and Methods of Use Thereof | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2017-11-23 | — | — | US | disclosed |
| US-9682983-B2 | BMP inhibitors and methods of use thereof | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682983-B2 | BMP inhibitors and methods of use thereof | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682983-B2 | BMP inhibitors and methods of use thereof | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160046633-A1 | BMP INHIBITORS AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2016-02-18 | — | — | US | disclosed |
| US-20160046633-A1 | BMP INHIBITORS AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2016-02-18 | — | — | US | disclosed |
| US-20160046633-A1 | BMP INHIBITORS AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2016-02-18 | — | — | US | disclosed |
| EP-2970311-A2 | BMP INHIBITORS AND METHODS OF USE THEREOF | The Brigham and Women's Hospital, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014160203-A2 | BMP INHIBITORS AND METHODS OF USE THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014160203-A2 | BMP INHIBITORS AND METHODS OF USE THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20100240647-A1 | Treatment of Alzheimer's Disease and Related Conditions | MERCK & CO., INC. | 2010-09-23 | — | — | US | disclosed |
| US-20100240647-A1 | Treatment of Alzheimer's Disease and Related Conditions | MERCK & CO., INC. | 2010-09-23 | — | — | US | disclosed |
| US-20100240647-A1 | Treatment of Alzheimer's Disease and Related Conditions | MERCK & CO., INC. | 2010-09-23 | — | — | US | disclosed |
| EP-1981509-B1 | Pyrazolo[1,5-a]pyrimidine derivatives for use in treatment of Alzheimer's disease and related conditions | MERCK SHARP & DOHME (GB) | 2010-03-17 | — | — | EP | disclosed |
| EP-1981509-B1 | Pyrazolo[1,5-a]pyrimidine derivatives for use in treatment of Alzheimer's disease and related conditions | MERCK SHARP & DOHME (GB) | 2010-03-17 | — | — | EP | disclosed |
| WO-2007085873-A1 | TREATMENT OF ALZHEIMER'S DISEASE AND RELATED CONDITIONS | MERCK SHARP & DOHME LIMITED (GB) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240647-A1 | Treatment of Alzheimer's Disease and Related Conditions | MAPT, MAP2, TTBK1 | PRKAB1 304/4885PRKAB2 342/4885PRKAG1 249/4885 |
| US-20160046633-A1 | BMP INHIBITORS AND METHODS OF USE THEREOF | BMP1, BMPR2, BMP2 | PRKAB1 3076/4885PRKAB2 3101/4885PRKAG1 3344/4885 |
| US-20170334918-A1 | BMP Inhibitors and Methods of Use Thereof | BMP1, BMPR2, BMP2 | PRKAB1 3076/4885PRKAB2 3101/4885PRKAG1 3344/4885 |
| US-10017516-B2 | BMP inhibitors and methods of use thereof | BMP1, BMPR2, BMP2 | PRKAB1 3076/4885PRKAB2 3101/4885PRKAG1 3344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.